期刊文献+

复方利福平片对结核分枝杆菌的抗菌作用

Antibacterial effect of compound rifampicin tablets on M.tuberculosis
下载PDF
导出
摘要 目的 :研究复方利福平片剂对结核分枝杆菌的体内、体外抗菌活性 ,并与抗结核药利福平进行比较。方法 :采用琼脂稀释法体外检测最小抑菌浓度 ( MIC) ;建立结核分枝杆菌的动物感染模型 ,观察药物在体内的保护作用。结果 :体外实验复方利福平对 2 6株结核分枝杆菌有抑制作用 ,复方利福平片剂中所含利福平的 MIC低于单纯利福平的 ;体内保护实验结果表明 ,阴性对照组感染小鼠半数存活时间 ( 5 0 % survival time,ST50 )为 1 7d,复方利福平片剂 ( 337.5 mg· kg-1)组其 ST50则达 2 9d。复方利福平片剂的病变指数分别为 0 .4、0 .34、0 .2 4 ;复方利福平片剂组与空白对照组相比肺重量指数差异有显著性 ( P<0 .0 1 )。结论 :复方利福平具有较好的抗菌活性。 Objective: To examine antibacterial effect of compound rifampicin tablets on isolates of M. tuberculosis in vitro and vivo, and compare it with rifampin. Methods: Use drug diluted Lowenstein Jensen agar medium to determine MIC in vitro and establish infected animal model of tuberculosis to examine protective effect of compound rifampicin tablets in vivo. Results: MIC of compound rifampicin tablets on 26 isolates of M.tuberculosis, especially concentration of rifampicn in compound rifampicin tablets was lower than that of rifampin in control.Results of animal protective test of compound rifampicn from infection with M.tuberculosis shown that ST 50 of compound rifampicin tablets was 29 d ,no significantly difference in comparison with rifampin, whereas ST 50 of control was 17 d ( P <0.01).Lesion index in tested group was ranged from 0 4 to 0 34 and to 0 24 finally, similar to that of rifampin, indicating extremely effectiveness , and weight index of lung was as similar as in rifampin, but less than that of control significantly. Conclusion: Results of experiments of compound rifampicin tablets in vivo and vitro shown effectively antituberculosis equivalent at least to that of rifampin.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2002年第4期377-379,共3页 Journal of Jilin University:Medicine Edition
关键词 复方利福平 最小抑菌浓度 抗菌作用 结核分枝杆菌 compound rifampicin tablets MCI antibacterial activity M.tuberculosis
  • 相关文献

参考文献7

  • 1International union against tuberculosis and lung disease. Antituberculosis regiments treatment of the IUATLD[J].Dull Int Union Tuberc Lung Dis,1988,63:60-64.
  • 2Rastogi N,Labrousse V,Goh KS.In vitro activities of fourteer antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages[J]. Curr Microbiol,1996,33(3):167-175.
  • 3潘晞.结核分支杆菌耐药性研究进展[J].中国防痨杂志,1997,19(1):43-46. 被引量:11
  • 4Sreevatsan S,Pan X,Zhang Y, et al.Analysis of the oxy R-ahpC region in isoniazid-resistant and susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities[J]. Antimicrob Agents Chemother,1997,41(3):600-606.
  • 5刘勇,张智洁,王群,党琢.抗结核药复方制剂的体外药效学研究[J].中华医院感染学杂志,2001,11(6):460-467. 被引量:6
  • 6房丽.抗结核药复方制剂的体外药效学探讨[J].中国公共卫生,2000,16(5):480-480. 被引量:3
  • 7Hong Kong Chest Service /BMRC.Controlled trial of 2-4 and 6 months of pyrazinamide in 6-month, three-times- weekly regimens for smear-positive pulmonary tuberculosis,including an assessment of a combined preparation of Isoniazid,Rifampin and Pyrazinamide[J].Am Rev Respir Dis,1991,143:700-706.

二级参考文献3

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部